Latvian drug prices could see a rise
This article was originally published in Scrip
There are still question marks on whether drug prices in Latvia will rise. Earlier this summer, the government abolished the "pharmacist owns pharmacy" rule, part of the national law on medicines adopted in 2001 and amended this year. Some quarters believed the rule could lead to an increase in drug prices because of likely pharmacy closures, but this fear has now lessened (scripintelligence.com, 19 August 2010).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.